DIVISLAB2021-07-012021-09-30in-bse-fin:OneOperatingExpenses01Member DIVISLAB2021-07-012021-09-30in-bse-fin:FourOperatingExpenses01Member DIVISLAB2021-07-012021-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DIVISLAB2021-07-012021-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DIVISLAB2021-07-012021-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member DIVISLAB2021-07-012021-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares DIVISLAB 2021-04-01 2022-03-31 2021-10-28 INR Lakhs Half yearly true Cash Flow Indirect Single segment Pharmaceuticals 2021-07-01 2021-09-30 Unaudited Consolidated 19875100000.00 191100000.00 20066200000.00 8765100000.00 0.00 -2216800000.00 2239800000.00 2100000.00 773500000.00 2906300000.00 12470000000.00 7596200000.00 0.00 7596200000.00 1355800000.00 175800000.00 1531600000.00 0.00 6064600000.00 0.00 0.00 0.00 0.00 6064600000.00 1800000.00 6066400000.00 6066400000.00 6066400000.00 0.00 530900000.00 2 22.84 22.84 0.00 0.00 22.84 22.84 1. The above Statement of consolidated unaudited financial results for the quarter and half year ended 30th September 2021, Statement of consolidated unaudited assets and liabilities as at 30th September, 2021 and Statement of consolidated unaudited cash flows for the half year ended 30th September, 2021 (‘Consolidated Statements’) are prepared in accordance with Indian Accounting Standards (‘Ind AS”) prescribed under section 133 of the Companies Act 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The same were, as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on 6th November, 2021. The same also were subjected to “limited review” by the Auditors of the Company and their report contains no qualification. 2. The consolidated unaudited results include the financial results of Divi’s Laboratories Limited and its two subsidiaries Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG (Referred as the “Group”). 3. The group is engaged in the manufacture of Active Pharmaceutical ingredients, intermediates, and nutraceutical ingredients and the same constitutes single reportable business segment as per Ind AS 108. 4. The Group does not have any discontinued operations and the Profit for the period represents the Profits from continuing operations only. 5. The Group has not experienced any significant impact on its operations, supply chain and recoverability of carrying amounts of financial and non-financial assets due to COVID 19 pandemic. As the pandemic continues to evolve, the Group will continue to closely monitor for any material changes to future economic conditions. 6. Forex gain included in Other Income and Loss included in Other Expenses for the respective periods is as given below: Rs. in lakhs Quarter ended Half Year ended Year ended 30.09.2021 30.06.2021 30.09.2020 30.09.2021 30.09.2020 31.03.2021 Forex gain/(loss) (712) 1964 (1563) 1252 (1082) (438) 7. Figures for the previous year/period have been reclassified/ regrouped wherever necessary to conform to current period’s classification. Single segment 2021-04-01 2021-09-30 Unaudited Consolidated 39481500000.00 479600000.00 39961100000.00 16608000000.00 64000000.00 -3702300000.00 4447800000.00 4900000.00 1506100000.00 5291600000.00 24220100000.00 15741000000.00 0.00 15741000000.00 3772800000.00 332500000.00 4105300000.00 0.00 11635700000.00 0.00 0.00 0.00 0.00 11635700000.00 19500000.00 11655200000.00 11655200000.00 11655200000.00 0.00 530900000.00 2 43.83 43.83 0.00 0.00 43.83 43.83 Other Expenses 2906300000.00 Other Expenses 5291600000.00 4900000.00 -5311200000.00 -1802300000.00 0.00 -755900000.00 -12300000.00 39500000.00 12500000.00 0.00 0.00 705700000.00 0.00 -676400000.00 1506100000.00 0.00 0.00 -16900000.00 0.00 54900000.00 -8100000.00 0.00 334700000.00 0.00 0.00 0.00 0.00 0.00 13200000.00 0.00 -6581000000.00 9160000000.00 0.00 0.00 0.00 3587800000.00 0.00 5572200000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3346400000.00 0.00 -106300000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 313700000.00 0.00 0.00 0.00 -2926400000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2800000.00 4000000.00 0.00 5309400000.00 4900000.00 0.00 0.00 -5321100000.00 -2675300000.00 20303200000.00 17627900000.00 0.00 17627900000.00